TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets

The Therapeutic Intensification in De Novo Leukaemia (TIDEL)-II study enrolled 210 patients with chronic phase chronic myeloid leukemia (CML) in two equal, sequential cohorts. All started treatment with imatinib 600 mg/day. Imatinib plasma trough level was performed at day 22 and if <1000 ng/mL,...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood
Päätekijät: Yeung, David T., Osborn, Michael P., White, Deborah L., Branford, Susan, Braley, Jodi, Herschtal, Alan, Kornhauser, Michael, Issa, Samar, Hiwase, Devendra K., Hertzberg, Mark, Schwarer, Anthony P., Filshie, Robin, Arthur, Christopher K., Kwan, Yiu Lam, Trotman, Judith, Forsyth, Cecily J., Taper, John, Ross, David M., Beresford, Jennifer, Tam, Constantine, Mills, Anthony K., Grigg, Andrew P., Hughes, Timothy P.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2015
Aiheet:
Clinical Trials and Observations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5161008/
https://ncbi.nlm.nih.gov/pubmed/25519749
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-07-590315
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia